ArticleDiscover oncology2026
Post-translational modification signature shapes the tumor immune microenvironment and predicts clinical outcomes in melanoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-translational modifications (PTMs) play a pivotal role in the initiation and progression of melanoma. To systematically evaluate their clinical significance, we integrated 10 widely used machine learning algorithms and 101 combinations to construct a PTM-related risk score model (PTMRS) based on 54 prognostic PTM genes. The model demonstrated robust prognostic predictive performance and stability across multiple melanoma cohorts (TCGA, GSE19234, GSE22153, GSE54467, and GSE65904). Immune profiling revealed that patients in the low-PTMRS group exhibited a more active immune microenvironment, characterized by increased infiltration of CD8⁺ T cells and M1 macrophages, along with reduced immune exclusion scores. Single-cell analysis further indicated that melanoma cells had the highest PTMRS scores, and distinct cell–cell communication patterns were observed between high and low PTMRS groups. ALG3, identified as a key gene positively correlated with PTMRS, was associated with poor prognosis and an immunosuppressive state. Immunohistochemistry and RT-qPCR results supported its potential oncogenic role in melanoma. Moreover, PTMRS was correlated with drug sensitivity across multiple compounds, suggesting its utility in guiding personalized therapeutic strategies. Collectively, the PTMRS model serves not only as an independent prognostic indicator for melanoma patients but also as a valuable tool for immune landscape assessment and targeted treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.